



TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/700,273	RECEIVED CENTRAL FAX CENTER FEB 27 2006
	Filing Date	November 03, 2003	
	First Named Inventor	Otmar KLINGLER et al.	
	Art Unit	1624	
	Examiner Name	BALASUBRAMANIAN, Venkataraman	
Total Number of Pages In This Submission	47	Attorney Docket Number	DEAV2002/0070 US NP

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	AVENTIS PHARMACEUTICALS INC.	
Signature		
Printed name	Joseph D. Rossi	
Date	February 27, 2006	Reg. No. 47,038

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300; Total No. of Pages Transmitted: 47)			
Signature			
Typed or printed name	Paul Irvine	Date	February 27, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
CENTRAL FAX CENTER
FEB 27 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
KLINGER, et al.

Examiner: V. Balasubramanian

Art Unit: 1624

Application No.: **10/700,273**

Filed: **November 3, 2003**

Title: **NOVEL PYRIMIDINE-4,6-
DICARBOXYLIC ACID DIAMIDES
FOR SELECTIVELY INHIBITING
COLLAGENASES**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, on

February 27, 2006

Date of Deposit

Signature 

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

REPLY TO ACTION PURSUANT TO 37 CFR § 1.111

This paper is responsive to the Action dated November 25, 2005 pursuant to 37 C.F.R. §
1.111 in connection with the above-identified patent application. Applicants respectfully request
that the application be amended, without prejudice, as follows:

- ☒ Amendments to the claims are reflected in the **Listing of Claims**, which begins
on page 2 of this paper.
- ☒ **Remarks/Arguments** begin on page 42 of this paper.